Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in
this population and to test the hypothesis that 6 months treatment with nilotinib will
significantly reduce pulmonary artery resistance.